MAPK7 and diabetes mellitus: An axis of ERK5/Nrf2 activation induced by statins such as fluvastatin reduces advanced glycation endproduct-induced VSMCs proliferation and migration, thus supporting the therapeutic potential of targeting the ERK5-Nrf2 signaling module in treating vascular lesions associated with diabetes [163].